1. No evidence for TSLP pathway activity in human breast cancer
- Author
-
Alix Scholer-Dahirel, Fabien Reyal, Carolina Martinez-Cingolani, Vassili Soumelis, Maude Guillot-Delost, Benjamin Sadacca, Lucia Pattarini, Paula Michea, Philémon Sirven, André Nicolas, Raphaël Zollinger, Cristina Ghirelli, Immunité et cancer (U932), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Curie-Université Paris Descartes - Paris 5 (UPD5), Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Immunology, University of Toronto, IGR Curie CIC 1428 - Center of Clinical Investigations, Institut Curie, Residual Tumor & Response to Treatment Laboratory (RT2Lab) - Translational Research Department, UMR 1152 - Statistiques and Génome du Laboratoire de Mathématiques et Modélisation d’Évry, Institut National de la Recherche Agronomique (INRA), Centre National de la Recherche Scientifique (CNRS), Université d'Evry Val d'Essonne, Department of Surgery, Columbia University College of Physicians and Surgeons, Platform of Investigative Pathology of Biopathology Department, Institut National de la Sante et de la Recherche Medicale [BIO2012-02, BIO2014-08], Fondation pour la Recherche Medicale, Association de la Recherche Contre le Cancer [PJA 20131200436], INCA [2011-1-PL BIO-12-IC-1, 2012-1-GYN-04-IC-1], CIC IGR-Curie [1428], [ANR-13-BSV1-0024-02], [ANR-10-IDEX-0001-02 PSL], [ANR-11-LABX-0043], Institut Curie-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Mathématiques et Modélisation d'Evry, Institut National de la Recherche Agronomique (INRA)-Université d'Évry-Val-d'Essonne (UEVE)-Centre National de la Recherche Scientifique (CNRS), Université Paris Descartes - Paris 5 (UPD5)-Institut Curie-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Mathématiques et Modélisation d'Evry (LaMME), and Université d'Évry-Val-d'Essonne (UEVE)
- Subjects
0301 basic medicine ,Stromal cell ,Thymic stromal lymphopoietin ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,Immunology ,Biology ,03 medical and health sciences ,Breast cancer ,thymic stromal lymphopoietin ,medicine ,Immunology and Allergy ,tumor microenvironment ,dendritic cells ,Original Research ,Tumor microenvironment ,Cancer ,medicine.disease ,Primary tumor ,cytokines ,3. Good health ,030104 developmental biology ,Cytokine ,Oncology ,Tumor progression - Abstract
Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine that primes dendritic cells for Th2 induction. It has been implicated in different types of allergic diseases. Recent work suggested that TSLP could play an important role in the tumor microenvironment and influence tumor progression, in particular in breast cancer. In this study we systematically assessed the production of TSLP at the mRNA and protein levels in several human breast cancer cell lines, large-scale public transcriptomics data sets, and primary human breast tumors. We found that TSLP production was marginal, and concerned less than 10% of the tumors, with very low mRNA and protein levels. In most cases TSLP was undetectable and found to be expressed at lower levels in breast cancer as compared to normal breast tissue. Last, we could not detect any functional TSLP receptor (TSLPR) expression neither on hematopoietic cells nor on stromal cells within the primary tumor microenvironment. We conclude that TSLP-TSLPR pathway activity is not significantly detected within human breast cancer. Taken together, these observations do not support TSLP targeting in breast cancer.
- Published
- 2016
- Full Text
- View/download PDF